ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

Company Overview

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Key Stats

• Today's Range: $0.40 to $0.48
• 50-Day Range: $0.42 to $0.79
• 52-Week Range: $0.40 to $2.60
• Volume: 367,669 shs
• Average Volume: 343,645 shs
• Market Capitalization: $12.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

ImmunoPrecise Antibodies Stock Analysis - MarketRank™

ImmunoPrecise Antibodies scored higher than 66% of companies evaluated by MarketBeat, and ranked 426th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ImmunoPrecise Antibodies has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.30) to ($0.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmunoPrecise Antibodies is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmunoPrecise Antibodies is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ImmunoPrecise Antibodies has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.67% of the float of ImmunoPrecise Antibodies has been sold short.

Short Interest Ratio / Days to Cover

ImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmunoPrecise Antibodies has recently decreased by 19.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmunoPrecise Antibodies does not currently pay a dividend.

Dividend Growth

ImmunoPrecise Antibodies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.67% of the float of ImmunoPrecise Antibodies has been sold short.

Short Interest Ratio / Days to Cover

ImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmunoPrecise Antibodies has recently decreased by 19.81%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

ImmunoPrecise Antibodies has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ImmunoPrecise Antibodies this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.

Percentage Held by Institutions

Only 6.70% of the stock of ImmunoPrecise Antibodies is held by institutions.

IPA Stock Analysis - Frequently Asked Questions

How have IPA shares performed this year?

ImmunoPrecise Antibodies' stock was trading at $1.71 at the beginning of 2024. Since then, IPA shares have decreased by 75.6% and is now trading at $0.4175.
View the best growth stocks for 2024 here.

How were ImmunoPrecise Antibodies' earnings last quarter?

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) issued its quarterly earnings data on Monday, September, 16th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02. The business had revenue of $3.85 million for the quarter, compared to the consensus estimate of $4.96 million. ImmunoPrecise Antibodies had a negative trailing twelve-month return on equity of 65.37% and a negative net margin of 114.67%.

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ImmunoPrecise Antibodies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoPrecise Antibodies investors own include NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), General Electric (GE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 9/16/2024
• Today: 11/02/2024
• Next Earnings (Estimated): 12/12/2024
• Fiscal Year End: 4/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IPA
• CUSIP: N/A
• CIK: 1715925
• Web: www.immunoprecise.com
• Phone: 250-483-0308
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +1,337.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,130,000.00
• Net Margins: -114.67%
• Pretax Margin: -123.51%
• Return on Equity: -65.37%
• Return on Assets: -40.29%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 0.99
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $18.16 million
• Price / Sales: 0.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.93 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 28,830,000
• Free Float: 26,863,000
• Market Cap: $12.04 million
• Optionable: Not Optionable
• Beta: 0.09